BioCentury
ARTICLE | Emerging Company Profile

ADx NeuroSciences: A progressive approach

ADx developing diagnostics for detection and prognosis of Alzheimer's

March 19, 2012 7:00 AM UTC

Current Alzheimer's disease diagnostics do not distinguish between different oligomers of tau and beta amyloid, and thus have little prognostic value. ADx NeuroSciences N.V. is developing oligomer-specific biomarkers that it expects not only to diagnose AD, but also provide information about prognosis.

The aggregation of beta amyloid and phosphorylated microtubule-associated protein tau (MAPT; tau; FTDP-17) are hallmarks of AD...